PMID- 18275497
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20151119
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 13
IP  - 2
DP  - 2008 Apr
TI  - Increased levels of serum matrix metalloproteinase-3 in haemodialysis patients 
      with dialysis-related amyloidosis.
PG  - 104-8
LID - 10.1111/j.1440-1797.2007.00845.x [doi]
AB  - BACKGROUND: It is recognized that matrix metalloproteinase-3 (MMP-3) is 
      abundantly expressed in active rheumatoid synovium, and that serum level of MMP-3 
      is a useful marker for diagnosis of rheumatoid arthritis and for evaluation of 
      prognosis in joint destruction. Little is known about serum MMP-3 levels in 
      haemodialysis (HD) patients, and thus, the association between serum MMP-3 and 
      dialysis-related amyloidosis (DRA) has yet to be elucidated. METHODS: Serum 
      levels of MMP-3 were measured by enzyme immunoassay in 150 HD patients, 90 
      without DRA and 60 with DRA, before HD. Simple regression analysis was performed 
      to investigate the relationship between serum level of MMP-3 and clinical 
      parameters, including age, HD duration, C-reactive protein and beta2 
      microglobulin (BMG). RESULTS: Serum levels of MMP-3 were significantly higher in 
      HD patients with DRA than in HD patients without DRA (258.2 +/- 118.1 vs 201.5 
      +/- 98.4 pg/mL, P = 0.0017), and both levels were significantly higher than those 
      of healthy subjects (45.6 +/- 13.4 pg/mL, P < 0.0001). Serum MMP-3 levels 
      significantly correlated with serum levels of BMG (r = 0.197, P = 0.0164) and HD 
      duration (r = 0.168, P = 0.0427). Moreover, serum MMP-3 levels significantly 
      correlated with serum BMG levels in HD patients without DRA (r = 0.341, P = 
      0.0012), but not in HD patients with DRA. CONCLUSION: Our results suggest that 
      matrix metalloproteinase activity increases in HD patients, which may be 
      associated with BMG and DRA.
FAU - Naganuma, Toshihide
AU  - Naganuma T
AD  - Department of Urology, Osaka City University Medical School, Osaka, Japan. 
      m9643361@msic.med.osaka-cu.ac.jp
FAU - Sugimura, Kazunobu
AU  - Sugimura K
FAU - Uchida, Junji
AU  - Uchida J
FAU - Tashiro, Koichiro
AU  - Tashiro K
FAU - Yoshimura, Rikio
AU  - Yoshimura R
FAU - Takemoto, Yoshiaki
AU  - Takemoto Y
FAU - Nakatani, Tatsuya
AU  - Nakatani T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Biomarkers)
RN  - 0 (beta 2-Microglobulin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Amyloidosis/*enzymology/etiology
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/enzymology/*therapy
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Renal Dialysis/*adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Up-Regulation
MH  - beta 2-Microglobulin/blood
EDAT- 2008/02/16 09:00
MHDA- 2008/03/28 09:00
CRDT- 2008/02/16 09:00
PHST- 2008/02/16 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2008/02/16 09:00 [entrez]
AID - NEP845 [pii]
AID - 10.1111/j.1440-1797.2007.00845.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2008 Apr;13(2):104-8. doi: 
      10.1111/j.1440-1797.2007.00845.x.